USFDA nod for Granules product

Granules India on Thursday said the U.S. Food and Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by the company’s wholly owned subsidiary Granules Pharmaceuticals Inc. for Butalbital, Acetaminophen and Caffeine capsules USP, 50 mg/300 mg/40 mg. The product is the bioequivalent to the reference-listed drug product (RLD), Butalbital, Acetaminophen and Caffeine capsules USP, 50 mg/300 mg/40 mg of Nexgen Pharma Inc. It is used for the relief of the symptom complex of tension (or muscle contraction) headache.

The approved product had U.S. sales of about $42 million MAT for the most recent 12 months ended in February 2020, a Granules release said citing IQVIA Health numbers.

A letter from the Editor

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism
Recommended for you
This article is closed for comments.
Please Email the Editor

Printable version | May 30, 2020 9:22:13 AM |

Next Story